Critics of California Stem-Cell Agency Address Institute of Medicine Panel
By Erika Check Hayden,
Nature News Blog
| 04. 13. 2012
[Quote's CGS's Marcy Darnovsky]
A
committee convened by the US Institute of Medicine (IOM) heard testimony on 10 April about shortcomings of the San Francisco-based California Institute for Regenerative Medicine (CIRM). And although members of the IOM committee asked probing questions about CIRM’s structure and performance, looming over the review is the reality that it’s difficult to make substantial revisions to some oft-criticized aspects of the agency, because the proposition that created CIRM makes it very difficult to change them.
That in itself is an important lesson, Stuart Drown of California’s Little Hoover Commission, a state oversight agency, told the IOM panel. “The most important takeaway is to really be careful what you lock yourself into in a proposition that carries the weight of constitutional law,” Drown said. He explained that in 2004, when voters approved the proposition that created CIRM, embryonic stem-cell research was under fire on the national stage, and that the proposition appeared to have been drafted to make the agency “bullet-proof” against detractors of stem-cell research.
Although it did achieve that goal, some provisions in the proposition have impeded the...
Related Articles
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...
By David Jensen [cites CGS' Pete Shanks], The California Stem Cell Report | 06.24.2024
Image by NIH Image Gallery from Flickr
The Biopolitical Times reported this month that the California stem cell and gene therapy program “seems to be in serious trouble.”
“On first glance, it may look impressive, with over a thousand patients...